GlassScriptPhysician profile
Joseph I Haider
NPI 1962943746
$3,868.65
in general payments reported to CMS, 2019-2025
25 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.62 · 2020: $116 · 2021: $640 · 2022: $568 · 2023: $1,076 · 2024: $794 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,515.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $677.93 | 2021-2025 | |
| Novo Nordisk INC | $657.69 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $593.70 | 2021-2025 | |
| Exact Sciences Corporation | $274.87 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $251.13 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $188.46 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $184.54 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $130.54 | 2021-2025 | Otezla, Repatha, Evenity |
| Allergan, INC. | $128.24 | 2019-2020 | |
| Silk Road Medical, INC. | $113.46 | 2021 | |
| Ablative Solutions, INC. | $110.82 | 2021 | |
| Astellas Pharma US INC | $94.10 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $81.13 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.65 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.50 | 2019-2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.31 | 2022-2023 | Xifaxan |
| Abbott Laboratories | $34.79 | 2023-2024 | Proclaim |
| Biohaven Pharmaceutical Holding Company LTD. | $29.06 | 2022 | |
| Insmed, INC. | $26.19 | 2025 | Arikayce |
| Amarin Pharma, INC. | $24.91 | 2021 | |
| Idorsia Pharmaceuticals US INC | $24.52 | 2023 | Quviviq |
| Boston Scientific Corporation | $21.86 | 2025 | Wavewriter Alpha Prime 16 |
| Viatris Specialty LLC | $15.83 | 2025 | Yupelri |
| Horizon Therapeutics Plc | $14.06 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Haider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.